by nobilistx | Apr 10, 2020 | Uncategorized |
We are all consumed by the escalating COVID-19 pandemic that is likely to become much worse in the coming weeks. However, given the situation in China, it is likely that within several months the situation will stabilize and we will begin the recovery process. But as...
by nobilistx | Feb 28, 2020 | Uncategorized |
February 28, 2020. Portland, Oregon. Nobilis Therapeutics has announced that it has fully endorsed the grant application to conduct an Investigator-Initiated Clinical Trial of NBTX-001 in patients with Obsessive Compulsive Syndrome (OCD). The grant has been submitted...
by nobilistx | Jan 3, 2020 | Uncategorized |
Nobilis Therapeutics will participate in the 38th Annual J.P. MORGAN Healthcare Conference that will take place on January 13-16, 2020. If you are interested in scheduling a meeting with Company’s CEO, Dr. Vlad Bogin, please email us at [email protected] We...
by nobilistx | Dec 25, 2019 | Uncategorized |
Please click on this link to view the full article
by nobilistx | Dec 6, 2019 | Uncategorized |
PORTLAND, ORE. (PRWEB) DECEMBER 06, 2019 Nobilis Therapeutics, a clinical stage biotechnology company focused on development of treatments for psychiatric and neurodegenerative disorders, announced today that the U.S. Food and Drug Administration (FDA) has cleared its...
by nobilistx | Dec 3, 2019 | Uncategorized |
Study results published in The Journal of Translational Medicine PORTLAND, Ore., December 3, 2019 — Nobilis Therapeutics, Inc. announced today the results of its preclinical study assessing the effects of its NBTX-001, a xenon-based therapeutic, in an animal...
